GSK: raises guidance for 2024

(CercleFinance.com) - GSK reports Q2 sales of £7.
88bn, up 10% y-o-y.

Sales were up across the board, with specialty medicines benefiting in particular from the launch of new products in oncology and HIV.

Adjusted core EBIT was £2.51bn, up 16%, giving core EPS of 43.4 pence, up 12%.

According to management, this underpins future growth and the company's confidence in its ability to bring meaningful innovation to patients.

For 2024, the company anticipates sales growth of +7% to +9% (vs. +5% to +7%) previously, with core EBIT expected between +11% and +13% (vs. +9% to +11% previously) and core EPS up +10% to +12% (vs. +8% to +10% previously).


Copyright (c) 2024 CercleFinance.com. All rights reserved.